{"success":true,"data":{"pressRelease":{"id":"82232","rtpr_id":"nGNX8M0Zvk","ticker":"ONCO","exchange":"NASDAQ","all_tickers":["ONCO"],"title":"Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation","author":"Globe Newswire","published_at":"2026-07-07T13:00:01.219Z","article_body":"Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve\nWellbeing and Address Loneliness Among Older Adults in UK Care Settings;\nRealbotix Becomes Accredited Supplier on Bloom’s Public Sector Marketplace;\nOnconetix Recently Entered into a Definitive Agreement to Acquire Realbotix\nLLC, a Subsidiary of Realbotix Corp.\n\nCINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq:\nONCO) (“Onconetix” or the “Company”) is providing the following\nsummary of a press release issued by Realbotix Corp., parent of Realbotix LLC\n(“Realbotix”), the target of Onconetix’s previously announced pending\nacquisition.\n\nRealbotix has announced a partnership with Bloom Procurement Services\n(“Bloom”), a UK public sector procurement specialist, to launch a pilot\nprogram deploying socially assistive humanoid robots to combat loneliness and\nimprove wellbeing among elderly residents in Northeast England.\n\nThe partnership will focus on care settings in Northeast England, where robots\nwill provide companionship, cognitive stimulation, emotional support, and\nroutine wellbeing check-ins. The program is designed to supplement, not\nreplace, human caregivers, and the robots feature natural conversation, eye\ncontact, facial expressiveness, and personalized interaction.\n\nThe evidence-based pilot will evaluate resident engagement, cognitive health\nindicators, staff feedback, and overall impact on loneliness and quality of\nlife.\n\nRealbotix has been accredited as a supplier on Bloom’s marketplace, creating\na compliant procurement route for UK public sector organizations to access\nRealbotix technology.\n\nAs previously announced on February 12, 2026, Onconetix entered into a\ndefinitive share exchange agreement to acquire 100% of the issued and\noutstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of\nRealbotix Corp., in an all-stock transaction. The combined company is expected\nto trade on Nasdaq following closing, which is anticipated to occur in the\nsecond half of 2026, subject to Onconetix shareholder approval, required\nregulatory approvals, and other closing conditions.\n\nThis communication includes information regarding Realbotix, a company that\nOnconetix has agreed to acquire, and is being provided for informational\npurposes only. Investors are cautioned not to place undue reliance on\nforward-looking or projected information.\n\nAbout Onconetix, Inc.\n\nOnconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company\nfocused on the research, development, and commercialization of innovative\noncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test\nfor prostate cancer originally developed by Proteomedix and approved for sale\nin the European Union under the IVDR, which it anticipates will be marketed in\nthe U.S. as a lab developed test through its license agreement with Labcorp.\nFor more information, visit www.onconetix.com.\n\nAbout Realbotix LLC\n\nRealbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT;\nFrankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending\nacquisition. Realbotix LLC develops AI-powered humanoid robots designed for\nhuman interaction across enterprise and consumer environments. Manufactured in\nthe United States, Realbotix’s patented AI and robotics technologies enable\nlifelike expressions, motion, vision, and social engagement. For more\ninformation, visit www.realbotix.ai.\n\nAdditional Information and Where to Find It\n\nIn connection with the proposed transaction between Realbotix and Onconetix,\nOnconetix intends to file with the SEC a Registration Statement on Form S-4\n(the “Registration Statement”) to register the common stock to be issued\nby Onconetix in connection with the proposed transaction. The Registration\nStatement will include a proxy statement of Onconetix and a prospectus of\nOnconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and\nOnconetix may file with the SEC other relevant documents concerning the\nproposed transaction. After the Registration Statement is declared effective,\nthe definitive Proxy Statement/Prospectus will be sent to the stockholders of\nOnconetix to seek their approval of the proposed transaction. This is not a\nsubstitute for the Registration Statement, the Proxy Statement/Prospectus or\nany other relevant documents that Realbotix or Onconetix has filed or will\nfile with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS\nAND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE\nREGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED\nTRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR\nSUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE\nTHEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE\nPROPOSED TRANSACTION, AND RELATED MATTERS.\n\nA copy of the Registration Statement, Proxy Statement/Prospectus, as well as\nother relevant documents filed by Realbotix and Onconetix with the SEC, may be\nobtained free of charge, when they become available, at the SEC’s website at\nwww.sec.gov. The information on Realbotix or Onconetix’s respective websites\nis not, and shall not be deemed to be, a part of this communication or\nincorporated into other filings either company makes with the SEC.\n\nParticipants in the Solicitation\n\nRealbotix, Onconetix and certain of their respective directors, executive\nofficers, and employees may be deemed to be participants in the solicitation\nof proxies in connection with the proposed transaction. Information about the\ndirectors and executive officers of Onconetix, their ownership of Onconetix\ncommon stock, and Onconetix’s transactions with related persons is set forth\nin the 10-K, as filed with the SEC on March 13, 2026, and other documents that\nmay be filed from time to time with the SEC. Additional information about the\ndirectors and executive officers of Realbotix and Onconetix and other persons\nwho may be deemed to be participants in the solicitation of stockholders of\nOnconetix in connection with the proposed transaction and a description of\ntheir direct and indirect interests will be included in the Proxy\nStatement/Prospectus related to the proposed transaction or other relevant\nmaterials, which will be filed with the SEC. These documents may be obtained\nfree of charge, when they become available, at the SEC’s website at\nwww.sec.gov and from Onconetix using the sources indicated above.\n\nNo Offer or Solicitation\n\nThis communication is for informational purposes only and is not intended to\nand does not constitute an offer to sell or the solicitation of an offer to\nbuy or sell any securities or the solicitation of any proxy, vote or approval,\nnor shall there be any sale of securities in any jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to registration or\nqualification under the securities laws of any such jurisdiction. No offer of\nsecurities shall be made except by means of a prospectus meeting the\nrequirements of Section 10 of the Securities Act, or in a transaction exempt\nfrom the registration requirements of the Securities Act.\n\nForward-Looking Statements\n\nCertain statements in this press release are forward-looking within the\nmeaning of the Private Securities Litigation Reform Act of 1995. These\nstatements may be identified by the use of forward-looking words such as\n“anticipate,” “believe,” “forecast,” “estimate,” “expect,”\nand “intend,” among others. These forward-looking statements (including,\nwithout limitation, the anticipated benefits and opportunities that may be\ngenerated by the proposed transaction described herein) are based on\nOnconetix’s current expectations and actual results could differ materially.\nThere are a number of factors that could cause actual events to differ\nmaterially from those indicated by such forward-looking statements. These\nfactors include, but are not limited to, the occurrence of any event, change,\nor other circumstances that could give rise to the right of one or both of the\nparties to terminate the share exchange agreement; the possibility that the\nproposed transaction does not close when expected or at all because the\nconditions to closing are not satisfied on a timely basis or at all, including\nthe failure to timely obtain stockholder approval for the proposed transaction\nfrom Onconetix’s stockholders, if at all; risks related to Onconetix’s\ncontinued listing on Nasdaq until closing of the proposed transaction; the\noutcome of any legal proceedings that may be instituted against Realbotix,\nOnconetix, or the combined company; the possibility that the anticipated\nbenefits of the proposed transaction are not realized when expected or at all;\nthe possibility that the vision, goals, and trajectory of the combined company\nare not timely achieved or realized or achieved or realized at all; the\npossibility that the proposed transaction may be more expensive or take longer\nto complete than anticipated, including as a result of unexpected factors or\nevents; the diversion of management’s attention from ongoing business\noperations and opportunities; changes in Onconetix’s stock price before\nclosing; and other factors that may affect future results of Realbotix,\nOnconetix, or the combined company. Onconetix does not undertake an obligation\nto update or revise any forward-looking statement. Investors should read the\nrisk factors set forth in Onconetix’s Annual Report on Form 10-K filed with\nthe SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the\nSEC on or after the date thereof. All of Onconetix’s forward-looking\nstatements are expressly qualified by all such risk factors and other\ncautionary statements. The information set forth herein speaks only as of the\ndate thereof.\n\n\n\nInvestor and Media Contact:\n\nOnconetix, Inc.\n\n201 E. Fifth Street, Suite 1900\n\nCincinnati, OH 45202\n\nPhone: (513) 620-4101\n\nEmail: investors@onconetix.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/4824d51d-2ecb-4f49-8b75-fe9b920e7b1c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8M0Zvk","title":"Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation","author":"Globe Newswire","ticker":"ONCO","created":"2026-07-07T13:00:01.219Z","tickers":["ONCO"],"exchange":"NASDAQ","article_body":"Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve\nWellbeing and Address Loneliness Among Older Adults in UK Care Settings;\nRealbotix Becomes Accredited Supplier on Bloom’s Public Sector Marketplace;\nOnconetix Recently Entered into a Definitive Agreement to Acquire Realbotix\nLLC, a Subsidiary of Realbotix Corp.\n\nCINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq:\nONCO) (“Onconetix” or the “Company”) is providing the following\nsummary of a press release issued by Realbotix Corp., parent of Realbotix LLC\n(“Realbotix”), the target of Onconetix’s previously announced pending\nacquisition.\n\nRealbotix has announced a partnership with Bloom Procurement Services\n(“Bloom”), a UK public sector procurement specialist, to launch a pilot\nprogram deploying socially assistive humanoid robots to combat loneliness and\nimprove wellbeing among elderly residents in Northeast England.\n\nThe partnership will focus on care settings in Northeast England, where robots\nwill provide companionship, cognitive stimulation, emotional support, and\nroutine wellbeing check-ins. The program is designed to supplement, not\nreplace, human caregivers, and the robots feature natural conversation, eye\ncontact, facial expressiveness, and personalized interaction.\n\nThe evidence-based pilot will evaluate resident engagement, cognitive health\nindicators, staff feedback, and overall impact on loneliness and quality of\nlife.\n\nRealbotix has been accredited as a supplier on Bloom’s marketplace, creating\na compliant procurement route for UK public sector organizations to access\nRealbotix technology.\n\nAs previously announced on February 12, 2026, Onconetix entered into a\ndefinitive share exchange agreement to acquire 100% of the issued and\noutstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of\nRealbotix Corp., in an all-stock transaction. The combined company is expected\nto trade on Nasdaq following closing, which is anticipated to occur in the\nsecond half of 2026, subject to Onconetix shareholder approval, required\nregulatory approvals, and other closing conditions.\n\nThis communication includes information regarding Realbotix, a company that\nOnconetix has agreed to acquire, and is being provided for informational\npurposes only. Investors are cautioned not to place undue reliance on\nforward-looking or projected information.\n\nAbout Onconetix, Inc.\n\nOnconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company\nfocused on the research, development, and commercialization of innovative\noncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test\nfor prostate cancer originally developed by Proteomedix and approved for sale\nin the European Union under the IVDR, which it anticipates will be marketed in\nthe U.S. as a lab developed test through its license agreement with Labcorp.\nFor more information, visit www.onconetix.com.\n\nAbout Realbotix LLC\n\nRealbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT;\nFrankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending\nacquisition. Realbotix LLC develops AI-powered humanoid robots designed for\nhuman interaction across enterprise and consumer environments. Manufactured in\nthe United States, Realbotix’s patented AI and robotics technologies enable\nlifelike expressions, motion, vision, and social engagement. For more\ninformation, visit www.realbotix.ai.\n\nAdditional Information and Where to Find It\n\nIn connection with the proposed transaction between Realbotix and Onconetix,\nOnconetix intends to file with the SEC a Registration Statement on Form S-4\n(the “Registration Statement”) to register the common stock to be issued\nby Onconetix in connection with the proposed transaction. The Registration\nStatement will include a proxy statement of Onconetix and a prospectus of\nOnconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and\nOnconetix may file with the SEC other relevant documents concerning the\nproposed transaction. After the Registration Statement is declared effective,\nthe definitive Proxy Statement/Prospectus will be sent to the stockholders of\nOnconetix to seek their approval of the proposed transaction. This is not a\nsubstitute for the Registration Statement, the Proxy Statement/Prospectus or\nany other relevant documents that Realbotix or Onconetix has filed or will\nfile with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS\nAND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE\nREGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED\nTRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR\nSUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE\nTHEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE\nPROPOSED TRANSACTION, AND RELATED MATTERS.\n\nA copy of the Registration Statement, Proxy Statement/Prospectus, as well as\nother relevant documents filed by Realbotix and Onconetix with the SEC, may be\nobtained free of charge, when they become available, at the SEC’s website at\nwww.sec.gov. The information on Realbotix or Onconetix’s respective websites\nis not, and shall not be deemed to be, a part of this communication or\nincorporated into other filings either company makes with the SEC.\n\nParticipants in the Solicitation\n\nRealbotix, Onconetix and certain of their respective directors, executive\nofficers, and employees may be deemed to be participants in the solicitation\nof proxies in connection with the proposed transaction. Information about the\ndirectors and executive officers of Onconetix, their ownership of Onconetix\ncommon stock, and Onconetix’s transactions with related persons is set forth\nin the 10-K, as filed with the SEC on March 13, 2026, and other documents that\nmay be filed from time to time with the SEC. Additional information about the\ndirectors and executive officers of Realbotix and Onconetix and other persons\nwho may be deemed to be participants in the solicitation of stockholders of\nOnconetix in connection with the proposed transaction and a description of\ntheir direct and indirect interests will be included in the Proxy\nStatement/Prospectus related to the proposed transaction or other relevant\nmaterials, which will be filed with the SEC. These documents may be obtained\nfree of charge, when they become available, at the SEC’s website at\nwww.sec.gov and from Onconetix using the sources indicated above.\n\nNo Offer or Solicitation\n\nThis communication is for informational purposes only and is not intended to\nand does not constitute an offer to sell or the solicitation of an offer to\nbuy or sell any securities or the solicitation of any proxy, vote or approval,\nnor shall there be any sale of securities in any jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to registration or\nqualification under the securities laws of any such jurisdiction. No offer of\nsecurities shall be made except by means of a prospectus meeting the\nrequirements of Section 10 of the Securities Act, or in a transaction exempt\nfrom the registration requirements of the Securities Act.\n\nForward-Looking Statements\n\nCertain statements in this press release are forward-looking within the\nmeaning of the Private Securities Litigation Reform Act of 1995. These\nstatements may be identified by the use of forward-looking words such as\n“anticipate,” “believe,” “forecast,” “estimate,” “expect,”\nand “intend,” among others. These forward-looking statements (including,\nwithout limitation, the anticipated benefits and opportunities that may be\ngenerated by the proposed transaction described herein) are based on\nOnconetix’s current expectations and actual results could differ materially.\nThere are a number of factors that could cause actual events to differ\nmaterially from those indicated by such forward-looking statements. These\nfactors include, but are not limited to, the occurrence of any event, change,\nor other circumstances that could give rise to the right of one or both of the\nparties to terminate the share exchange agreement; the possibility that the\nproposed transaction does not close when expected or at all because the\nconditions to closing are not satisfied on a timely basis or at all, including\nthe failure to timely obtain stockholder approval for the proposed transaction\nfrom Onconetix’s stockholders, if at all; risks related to Onconetix’s\ncontinued listing on Nasdaq until closing of the proposed transaction; the\noutcome of any legal proceedings that may be instituted against Realbotix,\nOnconetix, or the combined company; the possibility that the anticipated\nbenefits of the proposed transaction are not realized when expected or at all;\nthe possibility that the vision, goals, and trajectory of the combined company\nare not timely achieved or realized or achieved or realized at all; the\npossibility that the proposed transaction may be more expensive or take longer\nto complete than anticipated, including as a result of unexpected factors or\nevents; the diversion of management’s attention from ongoing business\noperations and opportunities; changes in Onconetix’s stock price before\nclosing; and other factors that may affect future results of Realbotix,\nOnconetix, or the combined company. Onconetix does not undertake an obligation\nto update or revise any forward-looking statement. Investors should read the\nrisk factors set forth in Onconetix’s Annual Report on Form 10-K filed with\nthe SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the\nSEC on or after the date thereof. All of Onconetix’s forward-looking\nstatements are expressly qualified by all such risk factors and other\ncautionary statements. The information set forth herein speaks only as of the\ndate thereof.\n\n\n\nInvestor and Media Contact:\n\nOnconetix, Inc.\n\n201 E. Fifth Street, Suite 1900\n\nCincinnati, OH 45202\n\nPhone: (513) 620-4101\n\nEmail: investors@onconetix.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/4824d51d-2ecb-4f49-8b75-fe9b920e7b1c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-07T13:00:01.302072347Z","server_sent_at_ms":1783429201302},"received_at":"2026-07-07T13:00:01.423Z","source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323233/0/en/Onconetix-Highlights-Realbotix-Partnership-with-Bloom-Services-to-Launch-UK-Pilot-Using-Humanoid-Robots-to-Combat-Elderly-Social-Isolation.html"},"analysis":{"id":"71320","press_release_id":"82232","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Acquisition of Realbotix is pending and subject to shareholder approval and regulatory conditions; no assurance of closing."],"eventType":"partnership","narrative":"Onconetix highlighted that its pending acquisition target, Realbotix, has partnered with Bloom Procurement Services to launch a pilot program deploying socially assistive humanoid robots in UK care settings.\n\nThe initiative, focused on Northeast England, aims to address elderly loneliness and is supported by Realbotix's new accreditation as a supplier on Bloom’s public sector marketplace.\n\nThe all-stock acquisition of Realbotix LLC by Onconetix is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Pending acquisition target Realbotix secures UK public sector pilot, validating commercial traction."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[],"products":["humanoid robots","Proclarix®"],"companies":[{"name":"Realbotix Corp.","ticker":"XBOT","relationship":"target parent company"},{"name":"Realbotix LLC","relationship":"acquisition target"},{"name":"Bloom Procurement Services","relationship":"partner"},{"name":"Labcorp","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The pending acquisition target, Realbotix, secured a tangible commercial pilot and public sector marketplace accreditation in the UK, validating the asset's traction ahead of the deal closing."},"tickerRelevance":{"others":[{"ticker":"XBOT","relevance":"target"},{"ticker":"76M0.F","relevance":"target"},{"ticker":"XBOTF","relevance":"target"}],"primary":"ONCO"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"target-commercial-pilot","issuerAuthored":true}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Onconetix highlighted that its pending acquisition target, Realbotix, has partnered with Bloom Procurement Services to launch a pilot program deploying socially assistive humanoid robots in UK care settings.\n\nThe initiative, focused on Northeast England, aims to address elderly loneliness and is supported by Realbotix's new accreditation as a supplier on Bloom’s public sector marketplace.\n\nThe all-stock acquisition of Realbotix LLC by Onconetix is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.","key_figures":null,"named_entities":{"people":[],"products":["humanoid robots","Proclarix®"],"companies":[{"name":"Realbotix Corp.","ticker":"XBOT","relationship":"target parent company"},{"name":"Realbotix LLC","relationship":"acquisition target"},{"name":"Bloom Procurement Services","relationship":"partner"},{"name":"Labcorp","relationship":"partner"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-07T17:00:09.839Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"target-commercial-pilot","issuerAuthored":true}},"durationMs":136565,"modelName":"george-droid-qwen-72b"}}